BioTissue announced an update to CAM360 AmnioGraft (CAM360 AG), its cryopreserved amniotic membrane therapy for mild to moderate ocular surface disease. According to a company press release, the new dual-tab design was developed based on real-world feedback to improve control and handling during membrane preparation and application.
Like the original CAM360 AG, the updated design uses BioTissue's proprietary cryopreservation technology to preserve the key biological properties of amniotic membranes. According to the company, the technology has been shown to support ocular surface healing through anti-inflammatory, anti-scarring, and anti-angiogenic actions1 and may be used across a range of ocular surface conditions, including dry eye disease, superficial punctate keratitis, and neurotrophic keratitis. OM


